Aflibercept for Retinopathy in the Real World (ARRoW) Study: Evaluation of Anti-VEGF Treatment for Diabetic Macular Oedema
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic macular oedema; Diabetic retinopathy
- Focus Therapeutic Use
- Acronyms ARRoW
- 02 May 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 08 Jul 2016 New trial record